Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort

Background Diagnosis of antiphospholipid syndrome (APS) is based on the positivity of laboratory criteria antiphospholipid antibodies (aPLs). Test results for aPLs could be contradictory among different detection methods as well as commercial manufacturers. This study aimed to assess and compare the diagnostic and analytic performances of four commercial assays prevalently used in China. Methods A total of 313 patients including 100 patients diagnosed with primary APS, 52 with APS secondary to SLE, 71 with SLE, and 90 health controls were recruited. Serum IgG, IgM, and IgA for aCL, and aβ2GPI antibodies were detected with two ELISA and two CLIA systems, and test system with the best diagnostic value was explored of its correlation with key clinical features. Results CLIA by YHLO Biotech Co. was considered as the system with the best predictive power, where 58.55 and 57.89% of APS patients were positive for aCL or aβ2GPI for at least one antibody (IgG or IgM or IgA). Overall, CLIA showed better performance characteristics than traditional ELISA test systems. Conclusion CLIA was considered as a better platform for aPL detection in APS diagnosis. A combination of other detection platforms could assist in differential diagnosis as well as in identifying high-risk patients.

[1]  Mengtao Li,et al.  Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population , 2020, Frontiers in Immunology.

[2]  K. Devreese.  How to Interpret Antiphospholipid Laboratory Tests , 2020, Current Rheumatology Reports.

[3]  K. Devreese.  Testing for antiphospholipid antibodies: Advances and best practices , 2020, International journal of laboratory hematology.

[4]  D. Oliveira,et al.  The Issue of the Antiphospholipid Antibody Syndrome , 2020, Journal of clinical medicine research.

[5]  M. Aure,et al.  Two Novel Technologies for the Detection of Anti-cardiolipin and Anti β2–Glycoprotein Antibodies in the Real Life: Chemiluminescent in Comparison to the Addressable Laser Bead Immunoassays , 2020, Immunological investigations.

[6]  Shichang Zhang,et al.  Advances in the Research on Anticardiolipin Antibody , 2019, Journal of immunology research.

[7]  P. Luppa,et al.  Evaluation of the sensitivity and specificity of a novel line immunoassay for the detection of criteria and non-criteria antiphospholipid antibodies in comparison to established ELISAs , 2019, PloS one.

[8]  J. Musial,et al.  Influence of anticardiolipin and anti‐β2 glycoprotein I antibody cutoff values on antiphospholipid syndrome classification , 2019, Research and practice in thrombosis and haemostasis.

[9]  M. Ward,et al.  EULAR recommendations for the management of antiphospholipid syndrome in adults , 2019, Annals of the rheumatic diseases.

[10]  J. Gris,et al.  Detection of Anti-Cardiolipin and Anti-β2glycoprotein I Antibodies Differs between Platforms without Influence on Association with Clinical Symptoms , 2019, Thrombosis and Haemostasis.

[11]  P. Benedetti Panici,et al.  Antiphospholipid syndrome: An update on risk factors for pregnancy outcome. , 2018, Autoimmunity reviews.

[12]  L. Cui,et al.  The Clinical Performance of a New Chemiluminescent Immunoassay in Measuring Anti-β2 Glycoprotein 1 and Anti-Cardiolipin Antibodies , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[13]  J. Piette,et al.  Classification of primary antiphospholipid syndrome as systemic lupus erythematosus: Analysis of a cohort of 214 patients. , 2018, Autoimmunity reviews.

[14]  J. Musial,et al.  Identification of high thrombotic risk triple‐positive antiphospholipid syndrome patients is dependent on anti‐cardiolipin and anti‐β2glycoprotein I antibody detection assays , 2018, Journal of thrombosis and haemostasis : JTH.

[15]  S. Čučnik,et al.  Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements , 2018, Clinical Rheumatology.

[16]  D. Garcia,et al.  Diagnosis and Management of the Antiphospholipid Syndrome , 2018, The New England journal of medicine.

[17]  T. Ortel,et al.  Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH , 2018, Journal of thrombosis and haemostasis : JTH.

[18]  G. Mengozzi,et al.  Analytical and clinical comparison of different immunoassay systems for the detection of antiphospholipid antibodies , 2016, International journal of laboratory hematology.

[19]  M. Fritzler,et al.  Detection of autoantibodies using chemiluminescence technologies , 2015, Immunopharmacology and immunotoxicology.

[20]  R. Aster,et al.  Recommendations for the use of the non‐obese diabetic/severe combined immunodeficiency mouse model in autoimmune and drug‐induced thrombocytopenia: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[21]  K. Devreese.  Antiphospholipid antibody testing and standardization , 2014, International journal of laboratory hematology.

[22]  D. Villalta,et al.  Autoantibody profiling of patients with antiphospholipid syndrome using an automated multiplexed immunoassay system. , 2014, Autoimmunity reviews.

[23]  K. Devreese,et al.  Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti‐beta2‐glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome , 2012, International journal of laboratory hematology.

[24]  Mimi Y. Kim,et al.  Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. , 2012, Arthritis and rheumatism.

[25]  E. Lococo,et al.  Detection of antiphospholipid antibodies by automated chemiluminescence assay. , 2012, Journal of immunological methods.

[26]  K. Devreese,et al.  Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. , 2011, Thrombosis research.

[27]  S. Sciascia,et al.  Risk Scale for the diagnosis of antiphospholipid syndrome , 2011, Annals of the rheumatic diseases.

[28]  K. Devreese,et al.  Evaluation of three commercial ELISA kits for anticardiolipin and anti‐beta2‐glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome , 2011, International journal of laboratory hematology.

[29]  S. Iliceto,et al.  Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome , 2010, Journal of thrombosis and haemostasis : JTH.

[30]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[31]  J. Closset,et al.  Results of Silastic Ring Vertical Gastroplasty More Than 6 Years after Surgery: Analysis of a Cohort of 214 Patients , 2004, Obesity surgery.

[32]  G. Hughes,et al.  Seronegative antiphospholipid syndrome , 2003, Annals of the rheumatic diseases.